Logo image
Refractory Pediatric Fibrostenotic Eosinophilic Esophagitis Treated With Dupilumab
Journal article   Open access   Peer reviewed

Refractory Pediatric Fibrostenotic Eosinophilic Esophagitis Treated With Dupilumab

Gopinathan Gangadharan Nambiar, Riad Rahhal, Benjamin P. Davis, Yiqin Xiong and Donna Cheung
ACG case reports journal, Vol.9(11), e00887
11/11/2022
DOI: 10.14309/crj.0000000000000887
PMCID: PMC9663132
PMID: 36382335
url
https://doi.org/10.14309/crj.0000000000000887View
Published (Version of record) Open Access

Abstract

Eosinophilic esophagitis (EoE) is a progressive inflammatory disease of the esophagus. Untreated or uncontrolled disease over time can lead to the development of fibrosis and formation of strictures. Once the patient develops strictures, it is difficult to treat with the available medical therapies and will often require esophageal dilations. The Food and Drug Administration recently approved dupilumab for the treatment of EoE in patients older than 12 years. The clinical trials excluded patients with esophageal strictures. We describe a case of EoE with fibrostenotic stricture who had stricture resolution while on dupilumab therapy.
Esophagus Case Report

Details

Metrics

Logo image